Google
OPTEY 株価分析 — Opthea Limited (Healthcare >> Biotechnology)
OPTEY に関するよくある質問
OPTEYのROE（自己資本利益率）は？
Opthea LimitedのROEは0.00%です。
OPTEYの配当利回りは？
Opthea Limitedの配当利回りは0.00%です。
OPTEYの品質スコア（Quality Score）は？
当社のAIはOPTEYの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
OPTEYは今が買い時ですか？
当社AIのタイミングスコアは100点中3点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
OPTEYはどのセクターに属しますか？
Opthea LimitedはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
OPTEY AI Analysis Summary
Our AI summary for OPTEY: Opthea Limited (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 0.00%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 3/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.03
Price
0.01
(70.00%)
Day Change
|
|
|---|
OPTEY, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.03 |
| PBV / Sector |
-0.03 / 5.20
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
1407.162450000000
|
| Average 1W Daily Value |
1413.768200000000
|
| Timing Factors |
|
85% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:17 |
| Symbol | OPTEY |
| Name | OPTHEA LIMITED |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 171.00 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5.81 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Level 9, Melbourne, VIC, Australia, 3000
Phone: 61 3 9826 0399
Website: https://ceryvyn.com
Employees: -
Sector: Healthcare >> Biotechnology
Description: Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
